Want to see AU:AYA full AI Analyst Report?
AYA Stock Chart & Stats
AU$5.64
-AU$0.02(-0.35%)
At close: 4:00 PM EDT
AU$5.64
-AU$0.02(-0.35%)
Day’s Range― - ―
52-Week RangeAU$0.95 - AU$6.49
Previous CloseN/A
Volume465.77K
Average Volume (3M)878.02K
Market Cap
AU$656.74M
Enterprise ValueAU$516.08
Total Cash (Recent Filing)AU$76.67M
Total Debt (Recent Filing)AU$546.00K
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Aug 27, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding162,963,610
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.10Price Target Upside8.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$13.49M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet ResilienceA low and improving debt-to-equity ratio provides durable financial flexibility, lowering interest burden and preserving optionality to fund R&D or commercialization without immediate refinancing pressure. This structural balance-sheet strength supports multi-quarter execution while losses persist.
AI-enabled Cardiovascular Software Market FitOperating in AI-driven cardiovascular imaging positions the company in a structural growth market: demand for clinical decision-support and imaging automation is durable. Software delivery can scale without proportional cost increases, enabling long-term gross margin improvement once adoption and regulatory pathways advance.
Initial Commercial Traction / Revenue EmergenceReporting first revenue after prior nil sales and high percentage growth from a small base signals early commercial validation; durable benefit if the firm converts pilot users to recurring contracts. Early sales prove distribution and clinical uptake vectors that can be scaled over multiple quarters.
Bears Say
High Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow indicate material cash consumption that will require continued external funding. Over the medium term this raises dilution and refinancing risk, constrains marketing and commercialization pace, and limits the time to achieve self-sustaining operations without capital injections.
Persistent Material Operating LossesDeep and recurring operating losses demonstrate the business has not yet attained operating leverage or a clear path to break-even. Over multiple quarters this erodes runway and requires strategic progress on commercialization or cost structure to transform a development-stage model into a sustainable operating model.
Equity Erosion And Negative Returns On EquityDeclining shareholder equity and negative ROE reflect persistent value erosion from losses. This weakens the firm’s capital base, reduces financial cushion against shocks, and may limit access to debt markets or favorable financing terms until profitability or meaningful revenue scale is achieved.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.95 and its highest was AU$6.49 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$656.74M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Aug 27, 2026 which is in 23 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate is -0.06.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 162,963,610 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.166%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.10 (8.16% Upside)
AU$6.10 (8.16% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth AU$4.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
453.47%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.10
▲(8.16% Upside)
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
Alcidion Group Limited
―







